Test volume increased approximately fivefold from the first quarter of 2026.
Florida Medicaid coverage expanded access to nearly 90,000 annual births.
Management expects operating expenses to stay flat or decline in 2027.
On its third-quarter 2026 earnings conference call, held on Nov. 4, 2026, Sera (NASDAQ:SERA) reported that test volume for PreTRM, its blood test that predicts preterm birth risk, increased approximately fivefold from the first quarter of 2026. Expanding state Medicaid coverage and physician adoption are driving early commercial scale for the maternal health company.
Three key takeaways stand out for long-term investors.
State Medicaid programs pay for roughly 40% to 43% of U.S. births, making government policy the primary catalyst for diagnostic adoption. Securing fee schedule pricing in major markets allows the business to convert regulatory mandates into high-volume, reimbursed patient volume.
With nearly 90,000 Medicaid births and approximately 4 million Medicaid lives, Florida represents our largest reimbursed market opportunity to date.
-- Zhenya Lindgardt, President and Chief Executive Officer
Clinicians require significant time to transition from initial trial usage to making a novel diagnostic test a standard component of prenatal care. The commercial sales model relies on active field education and electronic record integrations to turn initial awareness into routine practice adoption.
Physicians moving from initial awareness and early interest to broad adoption and high-volume ordering is a process which we have seen take 12 months to 18 months.
-- Scott Gleason, Chief Financial Officer
Securing private insurance coverage requires demonstrating real-world utility and cost savings beyond government programs. Running paid pilot trials with large private insurers helps generate health economic data, paving the way for eventual nationwide reimbursement policies.
We currently have 4 active pilot programs underway, including 2 with major national health plans and are in discussions regarding a potential multistate 2027 implementation with one of the nation's largest managed care organizations.
-- Tiffany Inglis, Chief Medical Officer
Commercial momentum is expanding as field teams activate state coverage wins, supported by $72.8 million in cash that funds operations into fiscal year 2029. Management is prioritizing sales coverage in reimbursed regions while cutting administrative overhead to maintain strict capital discipline across the business.
On an overall basis, we believe we will see flat or down operating expenses in 2027 while significantly increasing the size of our commercial team.
-- Scott Gleason, Chief Financial Officer
Long-term growth hinges on securing clinical guideline inclusion, establishing kit-based international expansion by 2027, and expanding state Medicaid coverage. Management is executing its strategy to scale its diagnostic platform across commercial and government health channels.
We're building the infrastructure, capabilities and partnerships necessary to support long-term growth while maintaining a strong focus on operational efficiency and shareholder value creation.
-- Zhenya Lindgardt, President and Chief Executive Officer
Before you buy stock in Sera Prognostics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Sera Prognostics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $335,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,000,640!*
Now, it’s worth noting Stock Advisor’s total average return is 823% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 16, 2026.
The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.